Pliant Therapeutics
PLRX
114 hedge funds and large institutions have $59.7M invested in Pliant Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 39 reducing their positions, and 50 closing their positions.
22% more call options, than puts
Call options by funds: $133K | Put options by funds: $109K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10.65% less ownership
Funds ownership: 94.53% → 83.88% (-11%)
19% less funds holding
Funds holding: 140 → 114 (-26)
23% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 39
24% less capital invested
Capital invested by funds: $78.5M → $59.7M (-$18.8M)
52% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.33M |
| 2 |
JP Morgan Chase
New York
|
+$2.09M |
| 3 |
Millennium Management
New York
|
+$1.2M |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$992K |
| 5 |
Morgan Stanley
New York
|
+$992K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.05M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.05M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.45M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.09M |
PLRX Hedge Fund Activity: Q2 2025 in Review
114 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2025, worth a combined $59.7M — down 24% from $78.5M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of PLRX and 24 opened new positions — a net loss of 26 holders — while 39 trimmed existing stakes and 30 added.
The largest buyer was Citadel Advisors, adding an estimated $3.33M. The largest seller was BlackRock, cutting an estimated $4.4M.
- 114 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2025, down from 140 in Q1 2025.
- Funds reported $59.7M of Pliant Therapeutics stock for Q2 2025, down 24% quarter-over-quarter.
- 24 funds opened new Pliant Therapeutics positions in Q2 2025 and 50 closed out, a net change of -26 holders.
- The largest Pliant Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $3.33M added.
- The largest Pliant Therapeutics seller in Q2 2025 was BlackRock, an estimated $4.4M sold.
Based on aggregated 13F filings for Q2 2025.